Rheumatology 2002; 41: 471-473
© 2002 British Society for Rheumatology
Letters to the Editor |
Failure of G-CSF therapy in neutropenia associated with Sjögren's syndrome
Department of Internal Medicine,
1 Laboratory of Haematology and
2 Department of Ophthalmology, Clínica de Nuestra Señora del Pilar, Barcelona, Spain
SIR, Neutropenia is found in about 10% of patients who have Sjögren's syndrome (SS) [1]. An autoimmune mechanism has been invoked in its pathogenesis [2, 3]. It is usually mild, not requiring any therapy. Severe cases, complicated with opportunistic infections, are uncommon [2] and there is no established treatment. On the basis of the known effectiveness of granulocyte colony-stimulating factor (G-CSF) in autoimmune neutropenias [4], we attempted treatment with the recombinant G-CSF filgrastim in a patient with primary SS who developed life-threatening neutropenia. Progressive anaemia and thrombocytopenia led us to discontinue this treatment. Contrarily, the patient responded dramatically
Notes
References